News | December 24, 2025
Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The portfolio includes foundational patents on the production, composition, and commercial use of NR
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Full approval will depend on verification of clinical benefit in a confirmatory trial
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Subscribe To Our Newsletter & Stay Updated
